NON HODGKIN LYMPHOMA & CHRONIC LYMPHOCYTIC LEUKEMIA

Read 1237 times

1. Protocol Nο.: BAY 80-6946 / 17067 (CHRONOS-3)
A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

Study Locations in Greece:
Hematology Division - University Hospital of West Attica - Attikon, Athens
Hematology & Lymphoma, Bone Marrow Transplant Unit - Evangelismos Hospital, Athens
Hematology Division / First Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, “Laiko” General Hospital, Athens
Hematology Department - General Hospital of Thessaloniki G. Papanikolaou, Thessaloniki
Hematology Unit of Internal Medicine Dept. - University General Hospital of Patras

2. Protocol Nο.: ΒΑΥ 80-6946/17833 ( Chronos 4)
A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Study Locations in Greece:
Hematology Division - University Hospital of West Attica - Attikon, Athens
Hematology & Lymphoma, Bone Marrow Transplant Unit - Evangelismos Hospital, Athens
Hematology Division / First Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, “Laiko” General Hospital, Athens
Hematology Department - General Hospital of Thessaloniki G. Papanikolaou, Thessaloniki
Hematology Unit of Internal Medicine Dept. - University General Hospital of Patras

3. Protocol Nο.:ACE-LY-308
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma

Study Locations in Greece:
Hematology/Oncology Department 401 Military Hospital of Athens
Hematology Division - University Hospital of West Attica - Attikon, Athens
Hematology Division / First Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, “Laiko” General Hospital, Athens
Department of Hematology – Theagenio Cancer Hospital of Thessaloniki
Hematology Department - General Hospital of Thessaloniki G. Papanikolaou, Thessaloniki
Department of Hematology, Medical School, University of Ioannina
Hematology Unit of Internal Medicine Dept. - University General Hospital of Patras

4. Protocol No.: PCYC-1141-CA
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)

Study Locations in Greece:
Hematology Division / First Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, “Laiko” General Hospital, Athens
Hematology Department - General Hospital of Thessaloniki G. Papanikolaou, Thessaloniki
Hematology Unit of Internal Medicine Dept. - University General Hospital of Patras

5. Protocol No.: 20130109
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared With Rituximab in Subjects With CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL)

Study Locations in Greece:
Department of Hematology, Medical School, University of Ioannina
Hematology Unit of Internal Medicine Dept. - University General Hospital of Patras

6. Protocol No.: MO39107
A phase II study exploring the safety and efficacy of Atezolizumab administered in combination with Obinutuzumab or Rituximab anti-CD 20 therapy in patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL),Marginal Zone Lymphoma (MZL) and Waldenström Macroglobulinemia (WM)

Study Locations in Greece:
Hematology & Lymphoma, Bone Marrow Transplant Unit - Evangelismos Hospital, Athens

7.Protocol No.: 20150291
A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation

Study Locations in Greece:
Hematology & Lymphoma, Bone Marrow Transplant Unit - Evangelismos Hospital, Athens